30 years of historical data (1996–2025) · Healthcare · Medical - Care Facilities
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Chemed Corporation trades at 23.7x earnings, 18% below its 5-year average of 29.0x, sitting at the 63rd percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 7%. On a free-cash-flow basis, the stock trades at 18.3x P/FCF, 33% below the 5-year average of 27.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.0B | $6.2B | $8.0B | $8.9B | $7.7B | $8.4B | $8.7B | $7.3B | $4.8B | $4.1B | $2.7B |
| Enterprise Value | $6.0B | $6.2B | $8.0B | $8.8B | $7.9B | $8.7B | $8.7B | $7.5B | $4.8B | $4.2B | $2.8B |
| P/E Ratio → | 23.68 | 23.23 | 26.64 | 32.61 | 30.88 | 31.40 | 27.34 | 33.00 | 23.16 | 41.47 | 24.75 |
| P/S Ratio | 2.36 | 2.43 | 3.31 | 3.93 | 3.61 | 3.94 | 4.20 | 3.74 | 2.67 | 2.44 | 1.71 |
| P/B Ratio | 6.41 | 6.29 | 7.19 | 8.02 | 9.65 | 13.53 | 9.69 | 9.99 | 8.05 | 7.53 | 5.14 |
| P/FCF | 18.33 | 18.93 | 21.86 | 32.50 | 30.52 | 33.74 | 20.29 | 29.25 | 20.32 | 41.43 | 28.16 |
| P/OCF | 15.37 | 15.87 | 19.27 | 26.91 | 24.87 | 27.32 | 17.85 | 24.10 | 16.58 | 25.04 | 19.89 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Chemed Corporation's enterprise value stands at 15.0x EBITDA, 23% below its 5-year average of 19.5x. The Healthcare sector median is 14.2x, placing the stock at a 6% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.47 | 3.29 | 3.88 | 3.69 | 4.08 | 4.19 | 3.85 | 2.72 | 2.50 | 1.77 |
| EV / EBITDA | 15.00 | 15.48 | 18.64 | 21.87 | 19.57 | 21.69 | 19.51 | 24.69 | 17.15 | 27.97 | 13.06 |
| EV / EBIT | 17.88 | 17.45 | 19.96 | 24.84 | 23.57 | 24.77 | 21.86 | 28.07 | 19.81 | 34.32 | 15.42 |
| EV / FCF | — | 19.17 | 21.76 | 32.11 | 31.20 | 34.90 | 20.23 | 30.09 | 20.68 | 42.35 | 29.14 |
Margins and return-on-capital ratios measuring operating efficiency
Chemed Corporation earns an operating margin of 13.4%. Operating margins have compressed from 15.0% to 13.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 25.3% indicates solid capital efficiency. ROIC of 23.7% represents excellent returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.0% | 30.0% | 35.1% | 35.3% | 35.8% | 36.0% | 33.7% | 31.9% | 31.1% | 31.0% | 29.3% |
| Operating Margin | 13.4% | 13.4% | 15.1% | 15.0% | 16.1% | 16.0% | 18.7% | 13.3% | 13.7% | 6.8% | 11.3% |
| Net Profit Margin | 10.5% | 10.5% | 12.4% | 12.0% | 11.7% | 12.6% | 15.4% | 11.3% | 11.5% | 5.9% | 6.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 25.3% | 25.3% | 27.1% | 28.6% | 35.1% | 35.2% | 39.3% | 33.4% | 36.3% | 18.4% | 21.0% |
| ROA | 16.0% | 16.0% | 18.1% | 17.5% | 17.9% | 19.3% | 23.6% | 19.6% | 21.7% | 10.9% | 12.6% |
| ROIC | 23.7% | 23.7% | 26.4% | 25.9% | 27.3% | 28.8% | 32.3% | 23.9% | 28.0% | 13.6% | 22.2% |
| ROCE | 24.7% | 24.7% | 26.8% | 27.2% | 31.4% | 31.5% | 36.4% | 28.8% | 32.3% | 15.8% | 25.7% |
Solvency and debt-coverage ratios — lower is generally safer
Chemed Corporation carries a Debt/EBITDA ratio of 0.4x, which is very conservative (88% below the sector average of 3.2x). Net debt stands at $80M ($155M total debt minus $75M cash). Interest coverage of 204.3x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.16 | 0.13 | 0.14 | 0.31 | 0.52 | 0.15 | 0.30 | 0.15 | 0.19 | 0.21 |
| Debt / EBITDA | 0.38 | 0.38 | 0.33 | 0.39 | 0.61 | 0.80 | 0.30 | 0.71 | 0.32 | 0.68 | 0.51 |
| Net Debt / Equity | — | 0.08 | -0.03 | -0.10 | 0.22 | 0.47 | -0.03 | 0.29 | 0.14 | 0.17 | 0.18 |
| Net Debt / EBITDA | 0.20 | 0.20 | -0.09 | -0.27 | 0.43 | 0.72 | -0.06 | 0.69 | 0.30 | 0.61 | 0.44 |
| Debt / FCF | — | 0.25 | -0.10 | -0.40 | 0.68 | 1.16 | -0.06 | 0.85 | 0.36 | 0.92 | 0.98 |
| Interest Coverage | 204.30 | 204.30 | 225.42 | 113.73 | 72.92 | 188.53 | 169.15 | 58.69 | 49.02 | 28.37 | 48.66 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.05x means Chemed Corporation can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.61x to 1.05x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.05 | 1.05 | 1.38 | 1.61 | 0.92 | 0.76 | 1.10 | 0.73 | 0.83 | 0.91 | 0.99 |
| Quick Ratio | 1.03 | 1.03 | 1.35 | 1.57 | 0.88 | 0.73 | 1.08 | 0.70 | 0.80 | 0.88 | 0.96 |
| Cash Ratio | 0.26 | 0.26 | 0.62 | 0.85 | 0.25 | 0.11 | 0.54 | 0.02 | 0.03 | 0.06 | 0.09 |
| Asset Turnover | — | 1.54 | 1.46 | 1.36 | 1.48 | 1.59 | 1.45 | 1.53 | 1.83 | 1.81 | 1.79 |
| Inventory Turnover | 234.87 | 234.87 | 192.47 | 122.09 | 133.36 | 135.47 | 194.25 | 177.05 | 215.19 | 215.70 | 193.82 |
| Days Sales Outstanding | — | 26.34 | 25.70 | 29.26 | 23.83 | 23.41 | 22.26 | 27.08 | 24.47 | 24.89 | 30.56 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Chemed Corporation returns 7.7% to shareholders annually — split between a 0.5% dividend yield and 7.2% buyback yield. The payout ratio of 11.9% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 4.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.5% | 0.5% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.3% | 0.4% | 0.4% | 0.6% |
| Payout Ratio | 11.9% | 11.9% | 9.0% | 8.6% | 8.8% | 8.2% | 6.6% | 9.0% | 9.1% | 17.7% | 15.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.2% | 4.3% | 3.8% | 3.1% | 3.2% | 3.2% | 3.7% | 3.0% | 4.3% | 2.4% | 4.0% |
| FCF Yield | 5.5% | 5.3% | 4.6% | 3.1% | 3.3% | 3.0% | 4.9% | 3.4% | 4.9% | 2.4% | 3.6% |
| Buyback Yield | 7.2% | 7.0% | 4.5% | 0.8% | 1.5% | 6.8% | 2.0% | 1.3% | 3.3% | 2.3% | 3.8% |
| Total Shareholder Yield | 7.7% | 7.5% | 4.8% | 1.0% | 1.8% | 7.1% | 2.3% | 1.5% | 3.7% | 2.8% | 4.4% |
| Shares Outstanding | — | $14M | $15M | $15M | $15M | $16M | $16M | $17M | $17M | $17M | $17M |
Compare CHE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $6B | 23.7 | 15.0 | 18.3 | 30.0% | 13.4% | 25.3% | 23.7% | 0.4 | |
| $2B | 18.1 | 12.2 | 16.9 | 32.5% | 9.7% | 9.3% | 8.8% | 1.3 | |
| $9B | 26.3 | 23.5 | 24.2 | 13.7% | 8.6% | 16.9% | 7.0% | 7.7 | |
| $10B | 19.1 | 11.4 | 18.2 | 26.5% | 22.6% | 32.7% | 11.3% | 3.9 | |
| $605M | 11.7 | 9.4 | 15.1 | 35.1% | 23.5% | 22.2% | 9.3% | 4.6 | |
| $2B | 28.3 | 23.1 | 11.8 | 13.0% | 2.6% | 11.7% | 9.0% | 0.4 | |
| $3B | 17.3 | 7.9 | 13.3 | 18.1% | 6.0% | 15.2% | 15.3% | — | |
| $364B | 30.3 | 17.9 | 22.6 | 18.5% | 4.2% | 11.8% | 9.2% | 3.4 | |
| $43B | 36.7 | 22.9 | 115.5 | 14.5% | 1.1% | 7.0% | 4.1% | 5.7 | |
| $125B | 70.7 | 14.0 | 16.1 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 | |
| $90B | 19.6 | 13.2 | 15.8 | 3.6% | 1.6% | — | 254.1% | 1.2 | |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CHE stock.
Chemed Corporation's current P/E ratio is 23.7x. The historical average is 22.6x. This places it at the 63th percentile of its historical range.
Chemed Corporation's current EV/EBITDA is 15.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.3x.
Chemed Corporation's return on equity (ROE) is 25.3%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 18.4%.
Based on historical data, Chemed Corporation is trading at a P/E of 23.7x. This is at the 63th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Chemed Corporation's current dividend yield is 0.50% with a payout ratio of 11.9%.
Chemed Corporation has 30.0% gross margin and 13.4% operating margin. Operating margin between 10-20% is typical for established companies.
Chemed Corporation's Debt/EBITDA ratio is 0.4x, indicating low leverage. A ratio below 2x is generally considered financially healthy.